On February 8th, the EDQM will hold a dedicated session jointly organised with the European Medicines Agency on the role of the European Pharmacopoeia within the EU regulatory framework for biosimilars.
The event will be broadcast live, so that interested parties from all over the world will be able to follow the experts in real time and ask questions on the assessment of biosimilars in Europe, the role of monographs and their application. To attend, online or in person, and submit questions, please visit the event page.
The initiative is part of the commitment of the European Pharmacopoeia to ensuring the quality and safety of biotherapeutic products in Europe. The Ph. Eur. has driven the setting of quality standards for these products for more than two decades.